Ontology highlight
ABSTRACT:
SUBMITTER: Santoni M
PROVIDER: S-EPMC5992965 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
Santoni Matteo M Massari Francesco F Di Nunno Vincenzo V Conti Alessandro A Cimadamore Alessia A Scarpelli Marina M Montironi Rodolfo R Cheng Liang L Battelli Nicola N Lopez-Beltran Antonio A
Drugs in context 20180605
Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the development of immune-checkpoint inhibitors in cancer patients, including those with renal cell carcinoma (RCC). The optimal combination between immunotherapy and targeted agents (as well as the possible favourable sequential therapy of these two classes of drugs) remains an open question at this moment. Several trials are currently underway to assess the combination of anti-programmed-death 1 (PD-1) or ...[more]